WEIGAO GROUP (01066) spent 0.8032 million Hong Kong dollars to repurchase 0.14 million shares on April 24.

WEIGAO GROUP (01066) announced that on April 24, 2025, it spent 0.8032 million Hong Kong dollars to repurchase 0.14 million shares...

Zhitong FinanceApr 24 05:12 ET

Zhitong Hong Kong Stock Repurchase Statistics | April 24

Hong Kong Stock Buyback Statistics | April 24

Zhitong FinanceApr 23 21:10 ET

The industry is hotly discussing the future trends of nuclear medicine, will Hybrid NewCo become a new model for the RDC Industry to venture abroad? | Industry Observation

① Today, the 2025 Future XDC New Drug Conference is held in Chengdu; ② Executives from companies such as Baillie Tianheng and Kelun Botai, along with numerous experts and scholars in the industry, will jointly discuss cutting-edge technologies in ADC/nuclear drug development, overseas strategies, and other Topics.

cls.cnApr 17 08:57 ET

Zhicheng Hong Kong Stock Buyback Statistics | April 17

Hong Kong Stock Repurchase Statistics | April 17

Zhitong FinanceApr 16 21:10 ET

Morgan Stanley: Raises the Target Price for WEIGAO GROUP (01066) to HKD 5.90 and maintains a "Shareholding" rating.

Morgan Stanley predicts that overall sales will grow by 9% and 7% in 2025 and 2026 respectively, with profit growth slowing down, as Morgan Stanley remains cautiously optimistic about the contribution of new products and regulatory impacts.

Zhitong FinanceApr 13 23:04 ET

Everbright: Import substitution is expected to accelerate, pay attention to the rising market share of domestic surgical robots.

Everbright stated that the import substitution is expected to accelerate, paying attention to the rise in market share of domestic surgical robots.

Zhitong FinanceApr 10 19:17 ET